Les Meilleurs doctors pour le traitement de goitre diffusif-toxique en Turquie - TOP-23 des médecins

Assoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.

Specializations

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

Education:

• Degree: Faculty of Medicine, Trakya University, 2009
• Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
• Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
• Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
• Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
• Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Education and Experience

• 1992 - 1998, Gaziantep University, Faculty of Medicine
• 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
• 2015 – 2024, Bağcılar Medipol Mega University Hospital
• 2024 – Present, Medipol Acıbadem Hospital

Specializations

Cancer Surgery

Pancreatic Surgery

Bile Duct Surgery

Bariatric Metabolic Surgery

Oncological Surgery

Breast Surgery

Gastric cancer

Colon cancer

Thyroid Cancer

Obesity Surgery

Diabetes Surgeries

Education

Ondokuz Mayıs University Faculty of Medicine (1991)

KTÜ Faculty of Medicine Farabi Hospital (Specialization.1998)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Surgery Training, 2002)

Istanbul University Çapa Faculty of Medicine (Laparoscopic Antireflux Surgery Training, 2006)

Istanbul University Cerrahpaşa Faculty of Medicine (General Surgery Clinic Advance Laparoscopic Surgery, Laparoscopic Bariatric Surgery, Morbid Obesity and Oncological Cancer Surgery Training, 2010i)

Dr. Tülay Omma, Associate Professor

Specialization: Endocrinology and Metabolic Diseases

Academic Background

• Medical Education: İnönü University, Faculty of Medicine (English Program), 1994–2001.
• Internal Medicine Residency: Haseki Training and Research Hospital, 2004–2010.
• Subspecialty in Endocrinology and Metabolism: Ankara Training and Research Hospital, 2013–2017.

Professional Experience

• Clinical Expertise: 
  • General Practitioner with administrative responsibilities, 2002–2004.
  • Specialist in Internal Medicine during mandatory service, 2010–2013.
  • Endocrinologist and Metabolic Disease Specialist at Ankara Training and Research Hospital (2017–2023).
  • Earned the title of Associate Professor in 2023, reflecting her academic and clinical excellence.
    Lokman Hekim Health Group 2023 (present) 

Scientific Contributions & Publications

• Research Output: 
  • Published over 20 articles in peer-reviewed international journals, with a strong focus on diabetes, thyroid disorders, and polycystic ovary syndrome.
  • Delivered numerous oral presentations and posters at national and international conferences.
• Citation Metrics: 
  • Total Citations: 166
  • H-index: 6
  • i10-index: 4

Awards & Recognitions

• Multiple prestigious accolades, including: 
  • Best Oral Presentation Award (2023): For groundbreaking research on COVID-19 vaccines and Graves’ Disease.
  • Best Poster Award (2021): For clinical insights into hypoparathyroidism in Turkey (HiPOPARATURK-NET Study).

Professional Memberships & Certifications

• Active member of leading organizations: 
  • European Society of Endocrinology (ESE) and its Young Endocrinologists & Scientists Committee (EYES).
  • Turkish Society of Endocrinology and Metabolism.
• Completed numerous advanced training programs, including certifications in clinical trials, biostatistics, and thyroid ultrasonography.

Clinical & Research Focus

Dr. Omma’s expertise spans:

• Diabetes management and its complications.
• Advanced thyroid disease diagnosis and treatment.
• Polycystic Ovary Syndrome (PCOS) and its metabolic implications.
• Investigating the relationship between diet and endocrine/metabolic disorders.

Docteur en médecine (1996-2003). Spécialisé en médecine interne hospitalière (2004-2009), en endocrinologie (2011-2015) et possède une expérience professionnelle dans divers hôpitaux en Turquie (2004-2019).